Corcept CEO sells 40K shares in 10b5-1 plan

Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff reported an open-market sale of 40,000 shares of Common Stock on May 1, 2026 at a weighted average price of $50.0965 per share.

Rhea-AI Filing Summary

Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff reported an open-market sale of 40,000 shares of Common Stock on May 1, 2026 at a weighted average price of $50.0965 per share. The transaction was executed indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, over which he has voting power pursuant to voting agreements.

The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024. Following this transaction, the trust holds 2,878,326 shares of Corcept Therapeutics Common Stock, for which Belanoff disclaims beneficial ownership except to the extent of his pecuniary interest.

Insider Trade Summary 10b5-1

Net Seller: 40,000 shares

Net Sell 1 txn

Insider BELANOFF JOSEPH K

Role Chief Executive Officer

Sold 40,000 shs ($2.00M)

Type	Security	Shares	Price	Value
Sale	Common Stock	40,000	$50.0965	$2.00M

Holdings After Transaction: Common Stock — 2,878,326 shares (Indirect, Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02)

Footnotes (3)

1. F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
2. F2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.35 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
3. F3. Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Key Figures

Shares sold: 40,000 shares Average sale price: $50.0965 per share Sale price range: $50.00 to $50.35 per share +2 more

5 metrics

Shares sold 40,000 shares Open-market sale on May 1, 2026

Average sale price $50.0965 per share Weighted average price for 40,000 shares sold

Sale price range $50.00 to $50.35 per share Range of actual prices within the transaction

Shares held after transaction 2,878,326 shares Indirectly held by revocable trust after sale

Net insider share change -40,000 shares Net-sell direction per transaction summary

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Revocable Living Trust, pecuniary interest

4 terms

Rule 10b5-1 trading plan financial

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"Represents the weighted average sale price for the entire number of shares sold."

Revocable Living Trust financial

"Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02"

pecuniary interest financial

"disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Corcept Therapeutics (CORT) report?

Corcept Therapeutics reported that CEO Joseph K. Belanoff executed an open-market sale of 40,000 shares of Common Stock. The shares were sold indirectly through a revocable living trust associated with him, as disclosed in a Form 4 insider filing.

At what price did the Corcept (CORT) shares sell in this Form 4?

The 40,000 Corcept shares were sold at a weighted average price of $50.0965 per share. Footnotes state that actual sale prices ranged from $50.00 to $50.35, with detailed breakdowns available from the issuer upon request.

Was the Corcept (CORT) CEO’s stock sale under a Rule 10b5-1 plan?

Yes. The filing states the transaction was made pursuant to a Rule 10b5-1 trading plan. That plan was adopted by CEO Joseph K. Belanoff on November 26, 2024 and was in effect at the time of this May 1, 2026 sale.

How many Corcept (CORT) shares does the trust hold after the sale?

After selling 40,000 shares, the revocable living trust holds 2,878,326 shares of Corcept Common Stock. The filing notes that Belanoff has voting power over these shares but disclaims beneficial ownership except to the extent of his pecuniary interest.

Is the Corcept (CORT) CEO’s ownership direct or indirect in this filing?

The reported holdings are indirect, classified under ownership code “I”. Shares are held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust, with Belanoff’s voting power defined by agreements and a disclaimer of full beneficial ownership.

What does the Corcept (CORT) Form 4 say about Belanoff’s pecuniary interest?

The Form 4 explains that Joseph K. Belanoff disclaims beneficial ownership of the trust’s shares, except to the extent of his pecuniary interest. This means his economic stake is limited to whatever financial interest he has in the trust’s holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/05/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BELANOFF JOSEPH K

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		S(1)		40,000	D	$50.0965(2)	2,878,326	I	Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.35 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

3. Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Joseph K. Belanoff	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)